March 2, 2020 / 2:43 PM / a month ago

BRIEF-VBI Vaccines Announces Dosing Of First Recurrent Gbm Patient In Phase 2A Study Of Cancer Vaccine Candidate In Combination With Gsk's Adjuvant System

March 2 (Reuters) - VBI Vaccines Inc:

* VBI VACCINES ANNOUNCES DOSING OF FIRST RECURRENT GBM PATIENT IN PHASE 2A STUDY OF CANCER VACCINE CANDIDATE, VBI-1901, IN COMBINATION WITH GSK’S AS01B ADJUVANT SYSTEM

* VBI VACCINES INC - EXPANDED IMMUNOLOGIC DATA, TUMOR AND CLINICAL RESPONSES FROM VBI-1901 WITH GM-CSF STUDY ARM EXPECTED Q2 2020

* VBI VACCINES INC - INITIAL IMMUNOLOGIC DATA FROM VBI-1901 WITH AS01(B) STUDY ARM EXPECTED Q4 2020

* VBI VACCINES INC - TWO-ARM PHASE 2A STUDY IS EXPECTED TO ENROLL 20 FIRST-RECURRENT GBM PATIENTS TO RECEIVE VBI’S CANCER VACCINE CANDIDATE, VBI-1901 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below